Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Fosnetupitant Chloride,Palonosetron,Dexamethasone
Therapeutic Area : Gastroenterology
Study Phase : Approved
Recipient : Helsinn Advanced Synthesis
Deal Size : Undisclosed
Deal Type : Agreement
Helsinn, Chugai renew partnership to sell AKYNZEO® in UK and Ireland
Details : The agreement aims to commercialise Akynzeo (combination of netupitant-palonosetron), for the treatment of chemotherapy-induced nausea and vomiting (CINV) in adult patients, in UK and Ireland.
Brand Name : Akynzeo
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 12, 2024
Lead Product(s) : Fosnetupitant Chloride,Palonosetron,Dexamethasone
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Recipient : Helsinn Advanced Synthesis
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?